Category Archives: News

SOM BIOTECH OBTAINS THE APPROVAL FROM REGULATORY AUTHORITIES TO CARRY OUT THE PHASE IIA CLINICAL TRIAL FOR TTR AMYLOIDOSIS

SOM Biotech has just obtained the approval from the Ethics Committee of Hopital Vall d’Hebron and the Spanish Medicines Agency (AEMPS) to start the Phase IIa clinical trial of its compound SOM0226 indicated for transthyretin Amyloidosis. This trial will be jointly coordinated by SOM Biotech and Vall d’Hebron Research Institute (VHIR). The principal investigator of …

4TH INTERNATIONAL MEETING OF PEOPLE AFFECTED BY ALS

SOM Biotech will attend the 4th International Meeting of People affected by ALS (Amyotrophic Lateral Sclerosis). Burgos (Spain), 6th-11th April 2014. SOM Biotech will take part in the 4th International Meeting of People with ALS and Researchers organized jointly by the Spanish Ministry of Health and the Association of People Affected by ELA. The sessions …

SOM BIOTECH AT BIO-EUROPE SPRING 2014

SOM Biotech attended Bio-Europe Spring 2014 in Turin. 2,000 high-level executives from pharma, biotech, venture capital firms, and service companies were present at this event and over 11,000 partnering meetings took place in just three days. SOM Biotech was able to meet several delegates from medium-big pharma companies. ( http://www.ebdgroup.com/bes/index.php)

SUBCRIBE TO OUR NEWSLETTER

    Name*
    Email*


    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.